510K EXEMPTION REGULATIONS

The FDA 510(k) exemption regulations refer to certain medical devices that are not required to undergo the 510(k) (premarket notification process).  These exemptions are designed to streamline the regulatory process for devices that are considered to pose minimal risk to patients and users.

Generally, medical device manufacturers must submit a 510(k) premarket notification to the FDA to demonstrate that their device is substantially equivalent to a legally marketed device (predicate device). But certain low-risk devices are exempt from the 510(k) process. These exemptions can apply to both Class I (general controls) and some Class II (special controls) devices.

Class I Devices: Most Class I devices are exempt from 510(k) requirements, subject to certain limitations. These devices are typically considered less critical devices and poses minimal risk.

Class II Devices: Some Class II devices are also exempt, but this is less common. These devices are considered to pose a moderate risk.

Even if a device is 510(k) exempt, it must still comply with other regulatory requirements such as:

Special Controls: For some Class II devices, specific special controls must be met even if the device is exempt from 510(k).

Devices are classified into various panels, each covering a specific medical specialty, to determine if they are exempt. FDA maintains a database where anyone can check if the device is 510K exempt or not.

Liberty Management Group Ltd, provides assistance with medical device establishment registration, device listings, label review and US agent service to foreign facilities.

Sudha S

Regulatory Consultant

Email : office@libertymanagement.us

www.fdahelp.ushttp://www.fdahelp.us

DRUG DE-LISTINGS

The FDA (Food and Drug Administration) in the United States is responsible for regulating pharmaceuticals, including the approval and potential delisting (withdrawal) of drugs from the market. Drugs can be delisted for several reasons, including safety concerns, lack of efficacy, or when manufacturers fail to comply with regulatory requirements.

If a company no longer markets the drugs for several reasons, then they must de-list it with marketing end date which is the expiration date of last lot manufactured.

All drug listings must be renewed between October 1st and December 31st every year.

Starting January 1st every year FDA will inactivate human drug listings that are not certified between the renewal period of October 1 to December 31.

In addition to that starting from July 1st every year, FDA will begin to inactivate human drug listings that remain active and certified after the June listing update, if it contains at least one establishment that is not currently registered.

A private label distributor (PLD) or finished drug manufacturer can certify the drug listing at any time during that window, including prior to the renewal of the registration of an underlying manufacturer.

Prior to the listing renewal, manufacturers must renew their registration between October 1st and December 31st each year.

If the manufacturer fails to renew their registration, the listings will be considered misbranded for being manufactured at an unregistered establishment.

In July, the FDA will inactivate those active listings which are still linked to an unregistered establishment.

FDA will send Prior notification to the labeler code contacts for any listing in jeopardy of being inactivated, to allow for an update.

FDA inactivation is not the same as de-listing of the drug.  As per FDA regulations, companies must de-list the products when they discontinue manufacturing it for commercial distribution.

Liberty Management Group provides assistance with drug establishment registration, drug listing and drug listing renewals, and de-listings.

Sudha S

Regulatory Consultant

Email : office@libertymanagement.us

www.fdahelp.us